{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:49:16Z","timestamp":1794534556540,"version":"4.9.1"},"reference-count":240,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.resinv.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T04:05:50Z","timestamp":1633061150000},"page":"709-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Yasuhiro","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Anraku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Gono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ichiyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Johkoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikazu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reoto","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshioki","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2021.04.011_bib1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.1984.03340360059032","article-title":"Landmark article May 23, 1942: diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. By Paul Klemperer, Abou D. Pollack and George Baehr","volume":"251","author":"Klemperer","year":"1984","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.resinv.2021.04.011_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/03009741003604542","article-title":"Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort","volume":"39","author":"Nakajima","year":"2010","journal-title":"IORRA. Scand J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/BOR.0000000000000544","article-title":"Recent progress in systemic sclerosis-interstitial lung disease","volume":"30","author":"Castelino","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3899\/jrheum.101002","article-title":"Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan","volume":"38","author":"Yamasaki","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/14397595.2015.1054081","article-title":"Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors","volume":"26","author":"Ishizuka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.berh.2016.03.002","article-title":"Mixed connective tissue disease","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1148\/radiology.210.2.r99ja15333","article-title":"Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients","volume":"210","author":"Akira","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2021.04.011_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005382-199623000-00002","article-title":"High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis","volume":"11","author":"Ikezoe","year":"1996","journal-title":"J Thorac Imag"},{"key":"10.1016\/j.resinv.2021.04.011_bib11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.resinv.2021.04.011_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1148\/radiology.188.2.8327704","article-title":"Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage","volume":"188","author":"Remy-Jardin","year":"1993","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2021.04.011_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1148\/radiol.2321030174","article-title":"Rheumatoid arthritis-related lung diseases: CT findings","volume":"232","author":"Tanaka","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2021.04.011_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2559.2004.01896.x","article-title":"Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis","volume":"44","author":"Tansey","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.resinv.2021.04.011_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1378\/chest.08-2572","article-title":"Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia","volume":"136","author":"Song","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib18","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","article-title":"Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","article-title":"Polymyositis-dermatomyositis-associated interstitial lung disease","volume":"164","author":"Douglas","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12890-018-0591-y","article-title":"Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?","volume":"18","author":"Yamakawa","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib21","series-title":"Spencer's pathology of the lung","first-page":"804","article-title":"The lungs in connective tissue disease","author":"Guinee","year":"2000"},{"key":"10.1016\/j.resinv.2021.04.011_bib22","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1172\/JCI28756","article-title":"Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis","volume":"116","author":"Rangel-Moreno","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.resinv.2021.04.011_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.10-0194","article-title":"Connective tissue disease-associated interstitial lung disease: a call for clarification","volume":"138","author":"Fischer","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2021.04.011_bib26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccm.2010.04.002","article-title":"Utility of bronchoalveolar lavage in evaluation of patients with\u00a0connective tissue diseases","volume":"31","author":"Kowal-Bielecka","year":"2010","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib30","first-page":"1253","article-title":"Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis","volume":"30","author":"Kuwana","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib31","first-page":"S19","article-title":"Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care","volume":"23","author":"Pincus","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12890-016-0358-2","article-title":"Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?","volume":"17","author":"Nurmi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","volume":"355","author":"Callen","year":"2000","journal-title":"Dermatomyositis. Lancet"},{"key":"10.1016\/j.resinv.2021.04.011_bib37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2021.04.011_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.resinv.2021.04.011_bib41","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in\u00a0anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3109\/s10165-012-0756-0","article-title":"Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis\/dermatomyositis","volume":"23","author":"Arai","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib46","doi-asserted-by":"crossref","first-page":"833.e1","DOI":"10.1016\/j.crad.2018.04.017","article-title":"HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): a comparative study among individual underlying diseases","volume":"73","author":"Tanaka","year":"2018","journal-title":"Clin Radiol"},{"key":"10.1016\/j.resinv.2021.04.011_bib47","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib48","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/s10165-011-0502-z","article-title":"Diffuse alveolar damage in patients with dermatomyositis: a six-case series","volume":"22","author":"Matsuki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib50","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib51","first-page":"141","article-title":"Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies","volume":"9","author":"Yoshifuji","year":"2015","journal-title":"Clin Med Insights Circulatory, Respir Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.65.4.403","article-title":"Interstitial pneumonitis in association with polymyositis and dermatomyositis","volume":"65","author":"Frazier","year":"1974","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","article-title":"Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia","volume":"30","author":"Kotani","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib54","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/rheumatology\/kev192","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib55","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y","article-title":"Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases","volume":"41","author":"Schnabel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib56","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves\u00a0lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2169\/internalmedicine.39.428","article-title":"Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis","volume":"39","author":"Tanaka","year":"2000","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib59","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib60","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/14397595.2013.852847","article-title":"Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases","volume":"24","author":"Ichiyasu","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010436","article-title":"Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report","volume":"97","author":"Endo","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2021.04.011_bib63","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2021.04.011_bib64","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11748-012-0106-3","article-title":"Living-donor lobar lung transplantation for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of a case","volume":"61","author":"Shoji","year":"2013","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2021.04.011_bib66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.resinv.2021.04.011_bib67","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resinv.2021.04.011_bib68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.resinv.2021.04.011_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120313","article-title":"Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study","volume":"10","author":"Hozumi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2021.04.011_bib70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/pin.12140","article-title":"Anti-glycyl tRNA synthetase antibody associated interstitial lung disease without symptoms of polymyositis\/dermatomyositis","volume":"64","author":"Hara","year":"2014","journal-title":"Pathol Int"},{"key":"10.1016\/j.resinv.2021.04.011_bib71","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.011_bib73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","article-title":"Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy","volume":"16","author":"Sasano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib74","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/modpathol.2010.65","article-title":"The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome","volume":"23","author":"Yousem","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.resinv.2021.04.011_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib76","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2021.04.011_bib77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2021.04.011_bib78","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib79","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2014-206076","article-title":"Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis","volume":"75","author":"Tashkin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib80","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0002-9343(90)90425-D","article-title":"Evaluation and management of scleroderma lung disease\u00a0using bronchoalveolar lavage","volume":"88","author":"Silver","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib81","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"Goh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib82","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib83","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib84","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib85","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/jtd.2017.02.48","article-title":"Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease","volume":"9","author":"Yamakawa","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib87","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib89","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib90","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib91","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib92","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2014an update from the pulmonary transplantation council of the international society for heart and lung transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.resinv.2021.04.011_bib94","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib95","first-page":"100","article-title":"Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib96","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib97","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral\u00a0cyclophosphamide in scleroderma-related interstitial\u00a0lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib98","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib99","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2021.04.011_bib100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous\u00a0tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib101","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib102","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label","volume":"57","author":"Sircar","year":"2018","journal-title":"RCT. Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib103","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2020.1751402","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: a Japanese population analysis of the SENSCIS trial","volume":"31","author":"Kuwana","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib106","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib107","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.resinv.2021.04.011_bib108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib109","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10067-006-0254-x","article-title":"Oral cyclophosphamide improves pulmonary\u00a0function in scleroderma patients with fibrosing alveolitis: experience in one centre","volume":"26","author":"Beretta","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib110","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib111","first-page":"286","article-title":"Extra-articular manifestations in rheumatoid arthritis","volume":"5","author":"Cojocaru","year":"2010","journal-title":"Maedica"},{"key":"10.1016\/j.resinv.2021.04.011_bib112","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ng.2231","article-title":"Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population","volume":"44","author":"Okada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.resinv.2021.04.011_bib113","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/ard.2007.075192","article-title":"Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells","volume":"67","author":"Makrygiannakis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib114","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib115","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01641-2018","article-title":"Telomere length and genetic variant associations with interstitial lung disease progression and survival","volume":"53","author":"Newton","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib116","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib117","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2017.04.002","article-title":"Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Natalini","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib119","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib120","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/09031936.00019210","article-title":"Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome","volume":"37","author":"Tsuchiya","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1378\/chest.130.1.22","article-title":"Quantitative analysis of fibroblastic foci in usual interstitial pneumonia","volume":"130","author":"Enomoto","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib122","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/jclinpath-2013-201442","article-title":"Usual\u00a0interstitial pneumonia-pattern fibrosis in surgical\u00a0lung\u00a0biopsies. Clinical, radiological and histopathological\u00a0clues to aetiology","volume":"66","author":"Smith","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.resinv.2021.04.011_bib123","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.lungcan.2007.06.013","article-title":"Lung cancer after exposure to disease modifying anti-rheumatic drugs","volume":"59","author":"Bernatsky","year":"2008","journal-title":"Lung Canc"},{"key":"10.1016\/j.resinv.2021.04.011_bib124","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib125","first-page":"167","article-title":"Leflunomide-induced interstitial lung disease (a systematic review)","volume":"30","author":"Raj","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib126","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarc\u00f3n","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib127","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","article-title":"Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases","volume":"103","author":"Suda","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib128","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre","volume":"56","author":"Yusof","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2021.04.011_bib131","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib132","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/1756-185X.13334","article-title":"Interstitial lung disease in non-sicca onset primary Sj\u00f6gren\u2019s syndrome: a large-scale case-control study","volume":"21","author":"Gao","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib133","article-title":"Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sj\u00f6gren syndrome patients: a case-control study","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2021.04.011_bib134","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","article-title":"A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sj\u00f6gren\u2019s syndrome-related interstitial lung disease in a Chinese population","volume":"37","author":"Dong","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib135","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.200403-417OC","article-title":"Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study","volume":"171","author":"Ito","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib136","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.130.5.1489","article-title":"Interstitial lung disease in primary Sj\u00f6gren syndrome","volume":"130","author":"Parambil","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073774","article-title":"Prognostic factors in interstitial lung disease associated with primary Sj\u00f6gren\u2019s syndrome: a retrospective analysis of 33 pathologically-proven cases","volume":"8","author":"Enomoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2021.04.011_bib138","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.21037\/jtd.2018.03.120","article-title":"Risk factors for primary Sj\u00f6gren syndrome-associated interstitial lung disease","volume":"10","author":"Wang","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib139","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.resinv.2014.02.003","article-title":"Features of usual interstitial pneumonia in patients with primary Sj\u00f6gren\u05f3s syndrome compared with idiopathic pulmonary fibrosis","volume":"52","author":"Enomoto","year":"2014","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.011_bib140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/16000617.0011-2016","article-title":"Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Flament","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2021.04.011_bib141","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib142","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1440-1843.2003.00445.x","article-title":"Bronchoalveolar lavage fluid cells in mixed connective tissue disease","volume":"8","author":"Enomoto","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.04.011_bib143","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0002-9343(81)90366-1","article-title":"The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients","volume":"71","author":"Haupt","year":"1981","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib144","series-title":"Systemic lupus erythematosus clinical manual","first-page":"290","author":"Hashimoto","year":"2017"},{"key":"10.1016\/j.resinv.2021.04.011_bib145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2214\/ajr.166.2.8553934","article-title":"High-resolution chest CT in systemic lupus erythematosus","volume":"166","author":"Fenlon","year":"1996","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.resinv.2021.04.011_bib146","first-page":"432","article-title":"Lung lesions in collagen disease","volume":"67","author":"Hama","year":"1990","journal-title":"Jpn J Clin Exp Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib147","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00005792-197509000-00003","article-title":"Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis","volume":"54","author":"Matthay","year":"1975","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2021.04.011_bib148","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-91-1-30","article-title":"Immunopathologic studies of pneumonitis in systemic lupus erythematosus","volume":"91","author":"Inoue","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib149","first-page":"388","article-title":"Pulmonary hemorrhage and immune-complex deposition in the lung. Complications in a patient with systemic lupus erythematosus","volume":"104","author":"Churg","year":"1980","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib150","first-page":"342","article-title":"Immunohistologic findings in the lung in systemic lupus erythematosus","volume":"101","author":"Rodr\u00edguez-Iturbe","year":"1977","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib151","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ajcp\/68.5.553","article-title":"Acute pulmonary complications in systemic lupus erythematosus. Immunofluorescence and\u00a0light microscopic study","volume":"68","author":"Pertschuk","year":"1977","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.resinv.2021.04.011_bib152","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/thorax.55.2.159","article-title":"Pleuropulmonary manifestations of systemic lupus erythematosus","volume":"55","author":"Keane","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2021.04.011_bib153","first-page":"1048","article-title":"Histopathological examination of interstitial lung lesions associated with systemic lupus erythematosus","volume":"13","author":"Hano","year":"1994","journal-title":"Respiration research"},{"key":"10.1016\/j.resinv.2021.04.011_bib154","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s13665-012-0028-7","article-title":"Connective tissue disease-associated interstitial lung disease: a review","volume":"1","author":"Gutsche","year":"2012","journal-title":"Curr Respir Care Rep"},{"key":"10.1016\/j.resinv.2021.04.011_bib155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0002-9343(92)90194-G","article-title":"Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns","volume":"93","author":"Groen","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib156","first-page":"469","article-title":"Clinical significance of IgG anti-Sm antibodies in patients with systemic lupus erythematosus","volume":"17","author":"Yasuma","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib157","first-page":"479","article-title":"Lupus pneumonitis and anti-SSA(Ro) antibodies","volume":"16","author":"Boulware","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib158","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.lpm.2010.11.004","article-title":"Pleural and pulmonary involvement in systemic lupus erythematosus","volume":"40","author":"Torre","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib159","series-title":"Bronchoalveolar lavage (BAL) method guideline","article-title":"The Japanese respiratory society; ministry of health, labor and welfare, intractable disease overcoming research project, diffuse lung disease research group","year":"2017"},{"key":"10.1016\/j.resinv.2021.04.011_bib160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0049-0172(90)90094-V","article-title":"A long-term study of interstitial lung disease in systemic lupus erythematosus","volume":"20","author":"Weinrib","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib161","series-title":"Pulmonary manifestation of systemic lupus erythematosus in dubois' lupus erythematosus","first-page":"673","author":"Wallace","year":"1997"},{"key":"10.1016\/j.resinv.2021.04.011_bib162","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccm.2010.05.001","article-title":"Pulmonary manifestations of systemic lupus erythematosus","volume":"31","author":"Kamen","year":"2010","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib163","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-5231(21)00660-2","article-title":"Pulmonary manifestations of the collagen vascular diseases","volume":"10","author":"Wiedemann","year":"1989","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib164","first-page":"730","article-title":"Respiratory disorders associated with systemic diseases. Lung lesions associated with SLE","volume":"29","author":"Dohi","year":"2010","journal-title":"Respiration research"},{"key":"10.1016\/j.resinv.2021.04.011_bib165","first-page":"495","article-title":"Pitfall lupus pneumonia","volume":"33","author":"Michi","year":"2014","journal-title":"Respiration research"},{"key":"10.1016\/j.resinv.2021.04.011_bib166","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2021.04.011_bib167","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0049-0172(05)80022-8","article-title":"Pulmonary alveolar hemorrhage in systemic\u00a0lupus\u00a0erythematosus","volume":"23","author":"Schwab","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib168","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005792-199705000-00005","article-title":"Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome","volume":"76","author":"Zamora","year":"1997","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2021.04.011_bib169","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1177\/0961203316646461","article-title":"Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution","volume":"25","author":"Wan","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.resinv.2021.04.011_bib170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1445-5994.2006.01055.x","article-title":"Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports","volume":"36","author":"Lim","year":"2006","journal-title":"Intern Med J"},{"key":"10.1016\/j.resinv.2021.04.011_bib171","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00063198-200009000-00007","article-title":"Interstitial lung disease in systemic lupus erythematosus","volume":"6","author":"Cheema","year":"2000","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib172","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1756-185X.2010.01592.x","article-title":"Rituximab and lupus interstitial lung disease: friend or foe?","volume":"14","author":"Efthimiou","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib173","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib174","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/s10165-007-0554-2","article-title":"Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases","volume":"17","author":"Okada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/CRIAI:29:3:219","article-title":"Intravenous immunoglobulin therapy and systemic lupus erythematosus","volume":"29","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resinv.2021.04.011_bib176","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ppul.23133","article-title":"Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases","volume":"50","author":"Braun","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.resinv.2021.04.011_bib177","first-page":"184","article-title":"Rare practice of pediatric respiratory illness (centering on interstitial pneumonia in children). Diagnosis and treatment of childhood interstitial pneumonia","volume":"23","author":"Hinuma","year":"2013","journal-title":"Journal of the Japanese Society of Pediatric Pulmonology"},{"key":"10.1016\/j.resinv.2021.04.011_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib179","series-title":"ANCA-related vasculitis practice guidelines 2017. Research project for overcoming intractable diseases by the Ministry of Health, Labor and Welfare","author":"Arimura","year":"2017"},{"key":"10.1016\/j.resinv.2021.04.011_bib180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1568-9972(03)00010-7","article-title":"Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides","volume":"2","author":"Csernok","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resinv.2021.04.011_bib181","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","article-title":"Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan","volume":"41","author":"Furuta","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib182","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/s10165-011-0525-5","article-title":"Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study","volume":"22","author":"Ozaki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib183","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2214\/AJR.18.20967","article-title":"Chest high-resolution CT findings of microscopic polyangiitis: a Japanese first nationwide prospective cohort study","volume":"213","author":"Suzuki","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.resinv.2021.04.011_bib184","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.00110109","article-title":"Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis","volume":"36","author":"Tzelepis","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1843.2004.00581.x","article-title":"Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides","volume":"9","author":"Homma","year":"2004","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.04.011_bib186","first-page":"51","article-title":"Interstitial lung disease with ANCA-associated vasculitis","volume":"9","author":"Katsumata","year":"2015","journal-title":"Clin Med Insights Circulatory, Respir Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib187","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/resp.12763","article-title":"Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with\u00a0idiopathic pulmonary fibrosis","volume":"21","author":"Hosoda","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.04.011_bib188","first-page":"210","article-title":"Pathology of chronic interstitial pneumonia in MPO-ANCA positive cases","volume":"3","author":"Hebisawa","year":"2008","journal-title":"Jpn J Chest Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199659","article-title":"Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias","volume":"13","author":"Hozumi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2021.04.011_bib190","series-title":"Idiopathic interstitial pneumonia diagnosis and treatment guide","article-title":"The Japan respiratory society diffuse lung disease diagnosis and treatment guidelines development committee","year":"2016"},{"key":"10.1016\/j.resinv.2021.04.011_bib191","series-title":"Research project for overcoming intractable diseases\u201d by the Ministry of Health, Labor and Welfare. Idiopathic pulmonary fibrosis treatment guidelines development committee. Idiopathic pulmonary fibrosis treatment guidelines 2017","year":"2017"},{"key":"10.1016\/j.resinv.2021.04.011_bib192","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib193","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.rmed.2019.03.011","article-title":"Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients","volume":"150","author":"Sambataro","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib194","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2021.04.011_bib195","series-title":"FDA approves first treatment for group of progressive interstitial lung diseases","year":"2020"},{"key":"10.1016\/j.resinv.2021.04.011_bib196","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib197","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib198","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib199","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.resinv.2021.04.011_bib201","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resinv.2021.04.011_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020293","article-title":"Lung infections in systemic rheumatic disease: focus on opportunistic infections","volume":"18","author":"Di Franco","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2021.04.011_bib203","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.34530","article-title":"Development and validation of a risk score for serious infection in patients with rheumatoid arthritis","volume":"64","author":"Crowson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib204","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib205","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/rheumatology\/keq279","article-title":"Infections in polymyositis and dermatomyositis: analysis of 192 cases","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib206","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis: a series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib207","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/rheumatology\/key150","article-title":"Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample","volume":"57","author":"Ram Poudel","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib208","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib209","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22575","article-title":"Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011","volume":"67","author":"Tektonidou","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2021.04.011_bib210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib211","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib212","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib213","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib214","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia under anti-tumor necrosis factor therapy (PAT) study group. Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib215","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2021.04.011_bib216","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib217","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/rheumatology\/ken231","article-title":"Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population","volume":"47","author":"Takizawa","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2021.04.011_bib218","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1183\/13993003.00829-2015","article-title":"Connective tissue diseases, multimorbidity and the ageing lung","volume":"47","author":"Spagnolo","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.011_bib219","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/BOR.0000000000000117","article-title":"Evaluation and management of gastrointestinal manifestations in scleroderma","volume":"26","author":"Kirby","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.resinv.2021.04.011_bib220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.2009.04190.x","article-title":"Review article: the gastrointestinal complications of myositis","volume":"31","author":"Ebert","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.resinv.2021.04.011_bib221","author":"Camus"},{"key":"10.1016\/j.resinv.2021.04.011_bib222","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.resinv.2017.01.002","article-title":"Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]","volume":"55","author":"Tokuda","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.011_bib223","article-title":"Combined usage of extracorporeal membrane oxygenation and double filtration plasmapheresis in amyopathic dermatomyositis patient with severe interstitial lung disease: a case report","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2021.04.011_bib224","first-page":"81","article-title":"A case of clinically amyopathic dermatomyositis treated with endotoxin adsorption and double membrane filtration plasma exchange","volume":"6","author":"Kuroiwa","year":"2017","journal-title":"Journal of Saitama Dialysis Society"},{"key":"10.1016\/j.resinv.2021.04.011_bib225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0049-0172(05)80005-8","article-title":"Treatment of hemorrhagic lupus pneumonitis with plasmapheresis","volume":"24","author":"Erickson","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2021.04.011_bib226","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.V1371977","article-title":"ANCA are pathogenic--oh yes they are!","volume":"13","author":"Falk","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.resinv.2021.04.011_bib227","first-page":"226","article-title":"A case of dermatomyositis thought to have caused transfusion-related acute pneumonopathy","volume":"37","author":"Nemoto","year":"2018","journal-title":"Japanese Journal of Apheresis"},{"key":"10.1016\/j.resinv.2021.04.011_bib228","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: complications and management","volume":"23","author":"Mokrzycki","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib229","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/0002-9610(94)90126-0","article-title":"Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber","volume":"167","author":"Aoki","year":"1994","journal-title":"Am J Surg"},{"key":"10.1016\/j.resinv.2021.04.011_bib230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cyto.2012.08.032","article-title":"Association between cytokine removal\u00a0by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"61","author":"Oishi","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.resinv.2021.04.011_bib231","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000287232","article-title":"Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study","volume":"29","author":"Abe","year":"2010","journal-title":"Blood Purif"},{"key":"10.1016\/j.resinv.2021.04.011_bib232","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1753465817708950","article-title":"Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies","volume":"11","author":"Ichiyasu","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib233","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib234","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2169\/internalmedicine.49.3491","article-title":"Role of non-invasive ventilation in managing life-threatening acute exacerbation of interstitial pneumonia","volume":"49","author":"Tomii","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2021.04.011_bib235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1843.2011.02051.x","article-title":"Potential benefits of early continuous positive pressure ventilation in patients with rapidly progressive interstitial pneumonia","volume":"17","author":"Yokoyama","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.04.011_bib236","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21037\/jtd.2018.12.114","article-title":"Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study","volume":"11","author":"Ito","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2021.04.011_bib237","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtcvs.2013.06.039","article-title":"Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia","volume":"147","author":"Gaudry","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2021.04.011_bib238","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13613-017-0320-3","article-title":"Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?","volume":"7","author":"Grasselli","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.resinv.2021.04.011_bib239","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.chest.2018.01.006","article-title":"Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease","volume":"153","author":"Gannon","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.04.011_bib240","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Prad\u00e8re","year":"2018","journal-title":"J Heart Lung Transplant"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:31:35Z","timestamp":1761949895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534521000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":240,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2212534521000824"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2021.04.011","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}